Bone xenografts
View Patent ↗The invention provides an article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into humans. The invention further provides a method for preparing a bone xenograft by removing at least a portion of a bone from a non-human animal to provide a xenograft (X); washing the xenograft in saline and alcohol; subjecting the xenograft to a cellular disruption treatment; and treating the xenograft with a glycosidase to remove surface carbohydrate moieties. The invention also provides an article of manufacture produced by the above identified method of invention. The invention further provides a bone xenograft for implantation into a human including a portion ( 10 ) of a bone from a nonhuman animal, wherein the portion has substantially no surface carbohydrate moieties which are susceptible to glycosidase digestion. Each xenograft of the invention has substantially the same mechanical properties as a corresponding native bone.
1. An article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into a human, produced by the process of
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol;
c. subjecting the xenograft to a cellular disruption treatment; and
d. digesting the xenograft with a glycosidase to remove a plurality of first surface carbohydrate moieties,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone.
2. The article of manufacture of claim 1 , further comprising the step of
prior to step c, piercing the xenograft.
3. The article of manufacture of claim 1 , further comprising the step of
following step c, treating the xenograft with a second enzyme.
4. The article of manufacture of claim 3 wherein the second enzyme is selected from the group consisting of ficin and trypsin.
5. The article of manufacture of claim 1 , further comprising the step of
following step c, treating the xenograft with one or more agents selected from the group consisting of anticalcification agents, antithrombotic agents, antibiotics, and growth factors.
6. The article of manufacture of claim 1 , further comprising the step of
following step c, sterilizing the xenograft.
7. The article of manufacture of claim 6 wherein the sterilizing step is selected from the group consisting of treatment with glutaraldehyde, treatment with formaldehyde, treatment with ethylene oxide, and treatment with propylene oxide.
8. The article of manufacture of claim 1 , further comprising the step of
following step d, treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties,
whereby the xenograft is substantially non-immunogenic.
9. The article of manufacture of claim 8 , wherein at least a portion of the capping molecules are a plurality of fucosyl molecules.
10. The article of manufacture of claim 8 , wherein at least a portion of the capping molecules are a plurality of n-acetyl glucosamine molecules.
11. The article of manufacture of claim 1 , wherein the glycosidase is a galactosidase.
12. The article of manufacture of claim 11 , wherein the galactosidase is an α-galactosidase molecule.
13. The article of manufacture of claim 1 , wherein the cellular disruption treatment comprises freeze/thaw cycling.
14. The article of manufacture of claim 1 , wherein the cellular disruption treatment comprises exposure to gamma radiation.
15. The article of manufacture of claim 1 further comprising the step of
following step c, exposing the xenograft to a crosslinking agent in a vapor form.
16. The article of manufacture of claim 1 further comprising the step of
following step c, treating the xenograft with a demineralization agent to remove substantially minerals from an extracellular matrix.
17. The article of manufacture of claim 1 further comprising the step of
following step c, adding an osteoinductive factor to the xenograft.
18. The article of manufacture of claim 1 further comprising the step of
following step c, adding a binding agent to the xenograft.
19. An article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into a human, produced by the process of
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol; and
c. subjecting the xenograft to at least one treatment selected from the group consisting of exposure to ultraviolet radiation, immersion in alcohol, ozonation, and freeze/thaw cycling,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone and is substantially non-immunogenic.
20. The article of manufacture of claim 19 , wherein the treatment comprises immersion in alcohol and freeze/thaw cycling.
21. An article of manufacture comprising a substantially non-immunogenic bone xenograft for implantation into a human, produced by the process of
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol; and
c. subjecting the xenograft to a sterilization treatment and a cellular disruption treatment,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone and is substantially non-immunogenic.
22. The article of manufacture of claim 21 wherein the cellular disruption treatment comprises freeze-thaw cycling.
23. The article of manufacture of claim 21 wherein the sterilization treatment comprises immersion in alcohol.
24. A method of preparing a bone xenograft for implantation into a human, which comprises
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol;
c. subjecting the xenograft to a cellular disruption treatment; and
d. digesting the xenograft with a glycosidase to remove a plurality of first surface carbohydrate moieties,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone.
25. The method of claim 24 , further comprising the step of
prior to step c, piercing the xenograft.
26. The method of claim 24 , further comprising the step of
following step c, treating the xenograft with a second enzyme.
27. The method of claim 26 wherein the second enzyme is selected from the group consisting of ficin and trypsin.
28. The method of claim 24 , further comprising the step of
following step c, treating the xenograft with one or more agents selected from the group consisting of anticalcification agents, antithrombotic agents, antibiotics, and growth factors.
29. The method of claim 24 , further comprising the step of
following step c, sterilizing the xenograft.
30. The method of claim 29 , wherein the sterilizing step is selected from the group consisting of treatment with glutaraldehyde, treatment with formaldehyde, treatment with ethylene oxide, and treatment with propylene oxide.
31. The method of claim 24 , further comprising the step of
following step d, treating a plurality of second surface carbohydrate moieties on the xenograft with a plurality of capping molecules to cap at least a portion of the second surface carbohydrate moieties,
whereby the xenograft is substantially non-immunogenic.
32. The method of claim 31 , wherein at least a portion of the capping molecules are a plurality of fucosyl molecules.
33. The method of claim 31 , wherein at least a portion of the capping molecules are a plurality of n-acetyl glucosamine molecules.
34. The method of claim 24 , wherein the glycosidase is a galactosidase.
35. The method of claim 34 , wherein the galactosidase is an α-galactosidase.
36. The method of claim 24 , wherein the cellular disruption treatment comprises freeze/thaw cycling.
37. The method of claim 24 , wherein the cellular disruption treatment comprises exposure to gamma radiation.
38. The method of claim 24 further comprising the step of
following step c, exposing the xenograft to a crosslinking agent in a vapor form.
39. The method of claim 24 further comprising the step of
following step c, treating the xenograft with a demineralization agent to remove substantially minerals from an extracellular matrix.
40. The method of claim 24 further comprising the step of
following step c, adding an osteoinductive factor to the xenograft.
41. The method of claim 24 further comprising the step of
following step c, adding a binding agent to the xenograft.
42. A method of preparing a bone xenograft for implantation into a human, which comprises
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol; and
c. subjecting the xenograft to at least one treatment selected from the group consisting of exposure to ultraviolet radiation, immersion in alcohol, ozonation, and freeze/thaw cycling,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone and is substantially non-immunogenic.
43. The method of claim 42 , wherein the treatment comprises immersion in alcohol and freeze/thaw cycling.
44. A method of preparing a bone xenograft for implantation into a human, which comprises
a. removing at least a portion of a bone from a non-human animal to provide a xenograft;
b. washing the xenograft in water and alcohol; and
c. subjecting the xenograft to a sterilization treatment and a cellular disruption treatment,
whereby the xenograft has substantially the same mechanical properties as a corresponding portion of a native bone and is substantially non-immunogenic.
45. The method of claim 44 , wherein the cellular disruption treatment comprises freeze/thaw cycling.
46. The method of claim 44 , wherein the sterilization treatment comprises immersion in alcohol.